Who is sponsoring NCT06837558?

NCT06837558 is sponsored by Assiut University.

What drugs are being tested in NCT06837558?

Interventions in NCT06837558: fibroblast growth factor 23.

What condition does NCT06837558 study?

NCT06837558 studies Bone Mineral Density and Lupus Nephritis Activity.

Is NCT06837558 still recruiting?

NCT06837558 is currently not yet recruiting. Last updated 20 February 2025.

Last reviewed 2025-02-20 · How we verify

NCT06837558

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictors of Bone Mineral Density in Lupus Nephritis Activity

Not yet recruiting Last updated 20 February 2025

What this trial tests

trial testing fibroblast growth factor 23 in Bone Mineral Density and Lupus Nephritis Activity in 100 participants. Not yet recruiting.

Timeline

1 April 2025

Primary endpoint
1 April 2027

1 May 2027

Quick facts

Lead sponsor	Assiut University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 April 2025
Primary completion	1 April 2027
Estimated completion	1 May 2027

Drugs / interventions tested

fibroblast growth factor 23

Conditions studied

Bone Mineral Density and Lupus Nephritis Activity — all drugs for Bone Mineral Density and Lupus Nephritis Activity →

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Bone Mineral Density and Lupus Nephritis Activity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our aim in this study is Correlation of histopathology of renal biopsy in SLE with lupus nephritis patients versus predictors of bone mineral density in active and inactive lupus nephritis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06837558 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 20 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06837558.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing